GLP-1 Drugs Improve Weight, Blood Sugar, and Heart Health in Children and Teens with Obesity or Diabetes
A meta-analysis of 18 trials found GLP-1 receptor agonists significantly reduced weight, HbA1c, and blood pressure in children and adolescents, with no increase in suicidal ideation but more GI side effects.
Quick Facts
What This Study Found
Across 18 RCTs (1,402 participants; mean age 13.7 years; 59.3% female; median treatment 0.51 years), GLP-1 RAs vs. placebo showed:
- HbA1c: -0.44% (95% CI: -0.68% to -0.21%)
- Fasting glucose: -9.92 mg/dL (95% CI: -16.20 to -3.64)
- Body weight: -3.02 kg (95% CI: -4.98 to -1.06)
- BMI: -1.45 (95% CI: -2.40 to -0.49)
- BMI SDS: -0.20 (95% CI: -0.36 to -0.05)
- BMI percentile: -7.24% (95% CI: -12.97% to -1.51%)
- Systolic blood pressure: -2.73 mmHg (95% CI: -4.04 to -1.43)
- GI adverse events: increased (log RR 0.75)
- Suicidal ideation/behaviors: no significant difference vs. placebo
All efficacy outcomes reached statistical significance, supporting GLP-1 RAs for pediatric use.
Key Numbers
How They Did This
Systematic review and meta-analysis following PRISMA guidelines. Searched PubMed, Embase, and Cochrane CENTRAL from inception through February 2025. Included 18 RCTs comparing GLP-1 RAs to placebo in children and adolescents under 18 with obesity, overweight, prediabetes, or T2D. Two independent reviewers extracted data and assessed risk of bias using Cochrane RoB2. Random-effects inverse variance models were used for all analyses.
Why This Research Matters
As pediatric obesity reaches epidemic proportions, safe and effective pharmacotherapy options are desperately needed. This comprehensive meta-analysis from JAMA Pediatrics provides the strongest evidence to date that GLP-1 drugs work in young people, with a favorable safety profile regarding the critical concern of mental health side effects.
The Bigger Picture
This meta-analysis arrives at a critical moment as GLP-1 drugs are being approved for younger age groups and pediatric obesity is increasingly recognized as a serious health crisis. The data supports expanding these treatments to children and teens while addressing parental and clinical concerns about safety, particularly mental health effects that have received media attention.
What This Study Doesn't Tell Us
The median treatment duration was only about 6 months — long-term safety and efficacy in growing children remain unknown. The total sample size (1,402) is relatively modest for a meta-analysis. Effects on growth, puberty, bone health, and long-term mental health development were not assessed. Most trials studied a limited age range (mean 13.7 years), with less data for younger children.
Questions This Raises
- ?What are the long-term effects of GLP-1 agonists on growth and development in children?
- ?Do the benefits persist after discontinuation, or is there weight regain similar to adults?
- ?Should GLP-1 agonists be considered first-line pharmacotherapy for pediatric obesity?
Trust & Context
- Key Stat:
- 1,402 participants across 18 RCTs The largest meta-analysis to date of GLP-1 agonists in children and adolescents, showing significant improvements across all glycemic, weight, and cardiometabolic outcomes
- Evidence Grade:
- This is a high-quality systematic review and meta-analysis of randomized controlled trials published in JAMA Pediatrics, representing the highest tier of clinical evidence. The Cochrane RoB2 tool was used for risk of bias assessment.
- Study Age:
- Published in 2025 with data through February 2025, this is the most current comprehensive evaluation of GLP-1 agonists in the pediatric population.
- Original Title:
- Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Published In:
- JAMA pediatrics, 179(12), 1308-1317 (2025)
- Authors:
- Kotecha, Pareeta(4), Huang, Wenxi, Yeh, Ya-Yun, Narvaez, Valerie Martino, Adirika, Darlene, Tang, Huilin, Bernier, Angelina V, Westen, Sarah C, Smith, Steven M, Bian, Jiang, Guo, Jingchuan
- Database ID:
- RPEP-11906
Evidence Hierarchy
Frequently Asked Questions
Are GLP-1 drugs safe for teenagers?
This meta-analysis of 18 clinical trials found that GLP-1 drugs significantly improved weight and metabolic health in young people ages 6-17 without increasing suicidal thoughts or behaviors. The main side effect was more stomach-related issues like nausea. However, long-term safety data in growing children is still limited.
How much weight can a child lose on GLP-1 medication?
In this analysis, children and teens on GLP-1 drugs lost an average of about 3 kg (6.6 lbs) more than those on placebo over a median of 6 months, with BMI dropping by 1.45 points and BMI percentile dropping by about 7 percentage points. Individual results vary, and these drugs work best alongside lifestyle changes.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11906APA
Kotecha, Pareeta; Huang, Wenxi; Yeh, Ya-Yun; Narvaez, Valerie Martino; Adirika, Darlene; Tang, Huilin; Bernier, Angelina V; Westen, Sarah C; Smith, Steven M; Bian, Jiang; Guo, Jingchuan. (2025). Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis.. JAMA pediatrics, 179(12), 1308-1317. https://doi.org/10.1001/jamapediatrics.2025.3243
MLA
Kotecha, Pareeta, et al. "Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis.." JAMA pediatrics, 2025. https://doi.org/10.1001/jamapediatrics.2025.3243
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and Safety of GLP-1 RAs in Children and Adolescents..." RPEP-11906. Retrieved from https://rethinkpeptides.com/research/kotecha-2025-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.